1廖天义,陈涛,张志钢.耳硬化症镫骨手术治疗进展[J].中华耳科学杂志,2013,11:165.

2 Ishai R,Halpin CF,Shin JJ,et al.Long-term incidence and degree of sensorineural hearing loss in otosclerosis[J].Otol Neurotol,2016,37:1489.

3 Sziklai I,Batta TJ,Karosi T.Otosclerosis:an organ-specific inflammatory disease with sensorineural hearing loss[J].Eur Arch Otorhinolaryngol,2009,266:1711.

4钱燕妮,赵守琴.耳硬化症的病因及治疗[J].听力学及言语疾病杂志,2010:404.

5 Grayeli AB,Escoubet B,Bichara M,et al.Increased activity of the diastrophic dysplasia sulfate transporter in otosclerosis and its inhibition by sodium fluoride[J].Otol Neurotol,2003,24:854.

6 Felix-Trujillo MM,Valdez-Martinez E,Ramirez JE,et al.Surgical and medical treatment of hearing loss in mixed otosclerosis[J].Ann Otol Rhinol Laryngol,2009,118:859.

7 Cruise AS,Singh A,Quiney RE.Sodium fluoride in otosclerosis treatment:review[J].J Laryngol Otol,2010,124:583.

8 Hentschel MA,Huizinga P,van der Velden DL,et al.Limited evidence for the effect of sodium fluoride on deterioration of hearing loss in patients with otosclerosis:a systematic review of the literature[J].Otol Neurotol,2014,35:1052.

9 Brookler K.Medical treatment of otosclerosis:rationale for use of bisphosphonates[J].Int Tinnitus J,2008,14:92.

10 Uppal S,Bajaj Y,Coatesworth AP.Otosclerosis 2:the medical management of otosclerosis[J].Int J Clin Pract,2010,64:256.

11 Quesnel AM,Seton M,Merchant SN,et al.Third-generation bisphosphonates for treatment of sensorineural hearing loss in otosclerosis[J].Otol Neurotol,2012,33:1308.

12黄如冰,吴晓林,俞娟.双磷酸盐相关性颌骨坏死12例临床分析[J].中华口腔医学研究杂志(电子版),2012,6:353.

13 Yasil S,Comlekci A,Guneri A.Further hearing loss during osteoporosis treatment with etidronate[J].Postgrad Med J,1998,74:363.

14 Pazianas M,Clark EM,Eiken PA,et al.Inflammatory eye reactions in patients treated with bisphosphonates and other osteoporosis medications:cohort analysis using a national prescription database[J].J Bone Miner Res,2013,28:455.

15 Radzki RP,Bienko M,Filip R,et al.The protective and therapeutic effect of exclusive and combined treatment with alpha-ketoglutarate sodium salt and ipriflavone on bone loss in orchidectomized rats[J].J Nutr Health Aging,2016,20:628.

16 Lv WT,Yang YH,Ma LQ,et al.Ipriflavone reverses the adverse effects of a low-calcium diet on the histology of the tibia in caged layers[J].Br Poult Sci,2014,55:207.

17 Sziklai I,Komora V,Ribari O.Double-blind study on the effectiveness of a bioflavonoid in the control of tinnitus in otosclerosis[J].Acta Chir Hung,1992,33:101.

18 Deyhim F,Smith B J,Soung DY,et al.Ipriflavone modulates IGF-I but is unable to restore bone in rats[J].Phytother Res,2005,19:116.

19 Bellei PM,Terra MM,Peters VM,et al.Effect of ipriflavone on wistar rats and their litters[J].Rev Bras Ginecol Obstet,2012,34:22.

20 Shahin D,El-Farahaty RM,Houssen ME,et al.Serum 25-OH vitamin D level in treatment-naive systemic lupus erythematosus patients:Relation to disease activity,IL-23and IL-17[J].Lupus,2017,26:917.

21 Liktor B,Szekanecz Z,Batta TJ,et al.Perspectives of pharmacological treatment in otosclerosis[J].Eur Arch Otorhinolaryngol,2013,270:793.

22 Karosi T,Sziklai I.Etiopathogenesis of otosclerosis[J].Eur Arch Otorhinolaryngol,2010,267:1337.

23 Rudic M,Keogh I,Wagner R,et al.The pathophysiology of otosclerosis:Review of current research[J].Hear Res,2015,330(Pt A):51.

24 Potocka-Baklazec M,Sakowicz-Burkiewicz M,Kuczkowski J,et al.Expression of TNF-alpha,OPG,IL-1beta and the presence of the measles virus RNA in the stapes of the patients with otosclerosis[J].Eur Arch Otorhinolaryngol,2015,272:1907.

25 Trune DR,Canlon B.Corticosteroid therapy for hearing and balance disorders[J].Anat Rec(Hoboken),2012,295:1928.

26 Niedermeyer HP,Zahneisen G,Luppa P,et al.Cortisol levels in the human perilymph after intravenous administration of prednisolone[J].Audiol Neurootol,2003,8:316.

27 Adachi K,Chole RA,Yee J.Indomethacin inhibition of middle ear bone resorption[J].Arch Otolaryngol Head Neck Surg,1991,117:267.

28 Sherman BE,Chole RA.First place——resident basic science award 1999.Effects of leukotriene and cyclo-oxygenase inhibition on adaptive bone remodeling in the middle ear[J].Otolaryngol Head Neck Surg,2000,123(1Pt 1):1.

29 Csomor P,Sziklai I,Karosi T.TNF-alpha receptor expression correlates with histologic activity of otosclerosis[J].Otol Neurotol,2009,30:1131.

30 Karosi T,Csomor P,Szalmas A,et al.Osteoprotegerin expression and sensitivity in otosclerosis with different histological activity[J].Eur Arch Otorhinolaryngol,2011,268:357.

31 Wu Q,Wang GP,Xie J,et al.Tumor Necrosis Factor-alpha-Induced Ototoxicity in Mouse Cochlear Organotypic Culture[J].PLoS One,2015,10:e127703.

32 Fuentes-Santamaria V,Alvarado JC,Melgar-Rojas P,et al.The role of glia in the peripheral and central auditory system following noise overexposure:contribution of TNF-alpha and IL-1beta to the pathogenesis of hearing loss[J].Front Neuroanat,2017,11:9.

33 Zehnder AF,Kristiansen AG,Adams JC,et al.Osteoprotegerin in the inner ear may inhibit bone remodeling in the otic capsule[J].Laryngoscope,2005,115:172.

34 Brookler K.Medical treatment of otosclerosis:rationale for use of bisphosphonates[J].Int Tinnitus J,2008,14:92.

35 Priyadarshi S,Ray CS,Biswal NC,et al.Genetic association and altered gene expression of osteoprotegerin in otosclerosis patients[J].Ann Hum Genet,2015,79:225.